Results of a Prospective Phase II Randomized Study of Deferasirox (Exjade (R)) to Prevent Iatrogenic Iron Overload in Patients Undertaking Induction/Consolidation Chemotherapy for Acute Myeloid Leukaemia (HREC/10/QRBW/135)

Kennedy, Glen A., Morris, Kirk, Pillai, Elango, Curley, Cameron, Butler, Jason P. and Durrant, Simon (2012). Results of a Prospective Phase II Randomized Study of Deferasirox (Exjade (R)) to Prevent Iatrogenic Iron Overload in Patients Undertaking Induction/Consolidation Chemotherapy for Acute Myeloid Leukaemia (HREC/10/QRBW/135). In: ASH Annual Meeting Abstracts. 54th Annual Meeting and Exposition of the American Society of Hematology (ASH), Atlanta, GA, United States, (). 8-11 December 2012.

Author Kennedy, Glen A.
Morris, Kirk
Pillai, Elango
Curley, Cameron
Butler, Jason P.
Durrant, Simon
Title of paper Results of a Prospective Phase II Randomized Study of Deferasirox (Exjade (R)) to Prevent Iatrogenic Iron Overload in Patients Undertaking Induction/Consolidation Chemotherapy for Acute Myeloid Leukaemia (HREC/10/QRBW/135)
Conference name 54th Annual Meeting and Exposition of the American Society of Hematology (ASH)
Conference location Atlanta, GA, United States
Conference dates 8-11 December 2012
Proceedings title ASH Annual Meeting Abstracts   Check publisher's open access policy
Journal name Blood   Check publisher's open access policy
Place of Publication Washington, DC, United States
Publisher American Society of Hematology
Publication Year 2012
Year available 2012
Sub-type Published abstract
Open Access Status
ISSN 0006-4971
1528-0020
Volume 120
Issue 21
Total pages 2
Language eng
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Conference Paper
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in Thomson Reuters Web of Science Article
Google Scholar Search Google Scholar
Created: Fri, 07 Jun 2013, 19:35:18 EST by System User on behalf of School of Medicine